Shares of aTyr Pharma, Inc. (NASDAQ:ATYR – Get Free Report) have been given a consensus rating of “Hold” by the six ratings firms that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, one has issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $5.00.
Several brokerages recently weighed in on ATYR. Wells Fargo & Company increased their price target on aTyr Pharma from $1.00 to $4.00 and gave the stock an “equal weight” rating in a report on Friday, November 6th. Freedom Broker cut shares of aTyr Pharma from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 6th. Royal Bank Of Canada cut their price objective on shares of aTyr Pharma to $6.00 and set a “sector perform” rating for the company in a research report on Friday, November 6th. Wall Street Zen upgraded shares of aTyr Pharma to a “hold” rating in a research report on Saturday, October 31st. Finally, Weiss Ratings cut shares of aTyr Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, September 16th.
Read Our Latest Research Report on ATYR
Institutional Inflows and Outflows
aTyr Pharma Stock Performance
Shares of ATYR stock opened at $7.56 on Friday. aTyr Pharma has a 52-week low of $4.07 and a 52-week high of $44.40. The stock’s 50-day moving average price is $11.12 and its 200 day moving average price is $23.37.
aTyr Pharma (NASDAQ:ATYR – Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The company reported ($7.43) EPS for the quarter, missing the consensus estimate of ($4.00) by ($3.43). The business had revenue of $235.23 million during the quarter, compared to analysts’ expectations of $2.50 million. As a group, equities research analysts anticipate that aTyr Pharma will post -22.96 EPS for the current year.
aTyr Pharma Company Profile
aTyr Pharma, Inc. (NASDAQ:ATYR) is a biotechnology company focused on developing therapies that modulate immune system activity. The company’s research is based on a class of naturally occurring proteins known as extracellular tRNA synthetases, which can influence biological processes involved in inflammation, tissue repair and immune regulation. aTyr’s lead product candidate is efzofitimod, an engineered protein therapeutic designed to target neuropilin-2 and regulate immune responses in the lungs.
See Also
- Five stocks we like better than aTyr Pharma
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
